Drug Profile
PVX 108
Alternative Names: Peanut allergy vaccine - Aravax; PVX-108Latest Information Update: 23 Feb 2023
Price :
$50
*
At a glance
- Originator Aravax
- Class Peptides; Vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Peanut hypersensitivity
Most Recent Events
- 09 Feb 2023 Phase-II clinical trials in Peanut hypersensitivity (In children, In adolescents) in Australia (Intradermal) (NCT05621317)
- 06 May 2022 Aravax plans a phase-II AVX-201 trial for Peanut hypersensitivity (In adolescents, In children) in Australia and USA (intradermal) in 2022 (https://www.aravax.com.au/clinical-trial)
- 09 Mar 2022 Aravax plans a phase II trial for Peanut hypersensitivity in USA and Australia (Intradermal)